Are you using real-world evidence?

Published on: Feb 1, 2023

Parexel’s experts offer a roadmap and best practices for current RWE applications across three development arenas:

  • Early asset planning
  • Clinical development: Meeting regulatory expectations
  • Medical marketplace: Demonstrating value in the real world

In each section of this playbook, we highlight examples of recent Parexel projects that illustrate the power of RWE to improve decision-making and to drive cost- and times-saving development strategies.


Get Exclusive PDF Access

Return to Insights Center

Related Insights

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Blog

AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression

Mar 19, 2024

Blog

Using ethical AI to streamline HEOR

Jan 26, 2024

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Podcast

RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Related Insights

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Blog

AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression

Mar 19, 2024

Blog

Using ethical AI to streamline HEOR

Jan 26, 2024

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Show more